ICVH 2016

GENERAL INFORMATION
The 2016 International Conference on Viral Hepatitis (ICVH 2016) is sponsored by the International Association of Providers of AIDS Care (IAPAC), in partnership with the University of California, San Francisco (UCSF) and the International Association for the Study of the Liver (IASL).

The annual conference is a forum for the presentation of state-of-the-art approaches to the clinical management of viral hepatitis, specifically hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, with the aim of supporting a wide variety of clinicians, including non-liver specialists, as they integrate scientific advances into real-world clinical practice settings.

ICVH 2016 is taking place at the Mission Bay Conference Center, which is located at 1675 Owens Street, San Francisco, CA 94143-3008.
 

PROGRAM
ICVH 2016 is focused on expanding the universe of clinicians who can manage hepatitis B virus (HBV) and hepatitis C virus (HCV) monoinfection and coinfection with HIV. The conference aims to improve patient outcomes by educating clinicians on practical, state-of-the-science strategies to optimize HBV and HCV treatment in a variety of clinical settings.

The conference Co-Chairs are Vicente Soriano, MD, PhD (Hospital Carlos III, Madrid, SPAIN) and Norah Terrault, MD, MPH (University of California, San Francisco, USA).

Featured topics on the ICVH 2016 program include:

• Viral Hepatitis: A Global Snapshot of Challenges and Opportunities
• HBV: When Will It Be a Curable Disease?
• Translating Clinical Trial Promise into Real-World HCV Treatment Success
• New Tools for Assessing HBV and HCV Disease Severity, Progression, and Regression
• Non-Alcoholic Steatosis: What Is It and How Do We Treat and Monitor?
• HCV and Organ Transplantation
• Treatment of HCV Cirrhotic Patients
• Treatment of HCV for Prevention of Transmission
• Recent Advances and Future Prospects in Therapy for Hepatocellular Carcinoma

PRESENTATIONS
Select conference presentations, which will be uploaded daily during the conference, will appear below as the meeting progresses. IAPAC requests that any use of these presentations should include citations to both the presenting authors and relevant conference information (e.g. International Conference on Viral Hepatitis, March 14-15, 2016, San Francisco).

MONDAY, March 14, 2016

WELCOME BY CONFERENCE CO-CHAIRS
Norah Terrault, MD, MPH
Vicente Soriano, MD, PhD

PLENARY – Viral Hepatitis: A Global Snapshot of Challenges and Opportunities
John Ward, MD

PLENARY – HBV: When Will It Be a Curable Disease?
Marion G. Peters, MD

KEYNOTE ADDRESS – After the Cure: Looking Ahead in HCV Management
Nancy S. Reau, MD
 

ORAL ABSTRACT SESSION 1: SOF/LDV

25 – Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M): A Comparative Analysis of the Phase-3 ION-3 Efficacy Data to Real World Effectiveness (RWE)

Norah Terrault presenting

15 – Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HCV/HIV-Coinfected Patients

Anne Luetkemeyer presenting

22 – A Single Tablet Regimen of Ledipasvir + Sofosbuvir is Efficacious and Well-Tolerated among People Receiving Opiate Substitution Therapy

Nancy Reau presenting
 

ORAL ABSTRACT SESSION 2: HCV Treatment Challenges

8 – Comorbidities and Co-Medications of Patients with Chronic Hepatitis C (CHC) under Specialist Care in the UK – Challenges for Scaling up HCV Treatment?

Ben Hudson presenting

42 – Bringing Hepatitis C Treatment into the Medical Home

Joanna Eveland presenting

36 – Real-World Effectiveness of Direct-Acting Antivirals for Hepatitis C among HIV-infected Patients with Genotype 1

Edward Cachay presenting
 

ORAL ABSTRACT SESSION 3: SOF/VPV (ASTRALs)

26 – A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve and -Experienced Genotype 1, 2, 4, 5, 6 HCV-Infected Patients with and without Cirrhosis: Results of the ASTRAL-1 Study

Anne Luetkemeyer presenting

27 – Sofosbuvir/Velpatasvir for the Treatment of HCV in Patients with Decompensated Liver Disease: The ASTRAL-4 Study

Norah Terrault presenting

33 – Sofosbuvir/Velpatasvir for 12 wks vs Sofosbuvir+Ribavirin for 24 Weeks in GT 3 HCV Patients: The Phase 3 ASTRAL-3 Study

Nancy Reau presenting
 

ORAL ABSTRACT SESSION 4: HCV Elimination

19 – Chronic Hepatitis C Virus (HCV) Burden in Rhode Island: Modelling Treatment Scale-Up and Elimination

Ayorinde Soipe presenting

29 – Seroreversion of HCV Antibodies in HIV-Positive Patients with Acute Hepatitis C following Sustained Virological Response

Vicente Soriano presenting

43 – Direct-Acting Antivirals against HCV Infection in Elderly patients: Are they so well Tolerated and Safe as We Thought?

Berta Pernas presenting
 

PLENARY – Viral Hepatitis in Children and Adolescents

Kathleen B. Schwarz, MD

PLENARY – Viral Hepatitis and Recreational Drug Users

Christian Ramers, MD

PLENARY – Viral Hepatitis and Pregnancy
Tram T. Tran, MD

COMPLICATED CASE STUDY SESSION 1 – Acute Viral Hepatitis

Daniel Fierer, MD
Anne F. Luetkemeyer, MD

COMPLICATED CASE STUDY SESSION 2 – Chronic Viral Hepatits
Edward Cachay, MD, MAS

PANEL DISCUSSION – Translating Clinical Trial Promise into Real-World HCV Treatment Success
Moderator: Vicente Soriano, MD, PhD
Panelist 1: Kosh Agarwal, MD
Panelist 2: Paul Pockros, MD

TUESDAY, March 15, 2016

PLENARY – New Tools for Assessing Disease Severity, Progression, and Regression
in HBV and HCV
Ji-Dong Jia, MD, PhD

PLENARY – Non-Alcoholic Steatohepatitis: What Is It and How Do We Treat and Monitor?
Zobair M. Younossi, MD, MPH

PLENARY – HCV and Organ Transplantation
Kosh Agarwal, MD

PANEL DISCUSSION – Treatment of HCV for Prevention and Transmission
Moderator: Vicente Soriano, MD, PhD
Panelist 1: Diana L. Sylvestre, MD
Panelist 2: Seng Gee Lim, MD, MBBS

PLENARY – Managing HCV Treatment Failure and Drug Resistance in Clinical Practice
Vicente Soriano, MD, PhD

PLENARY – Recent Advances and Future Prospectives for Therapy of Hepatocellular Carcinoma
Morris Sherman, PhD, MB

PLENARY – Treatment of HCV in Cirrhotic Patients
Norah Terrault, MD, MPH

PANEL DISCUSSION – Is HIV a Special Population in the Viral Hepatitis Context?
Moderator: Jennifer Price, MD
Panelist 1: Vicente Soriano, MD, PhD
Panelist 2: Maurizio Bonacini, MD

PANEL DISCUSSION – No One Left Behind: Optimizing the Viral Hepatitis Care Continuum
Moderator: Norah Terrault, MD, MPH
Panelist 1: Glen Pietrandoni, RPh
Panelist 2: Kelly Eagen, MD

CLOSING REMARKS – Bridging Barriers to Improve Viral Hepatitis Outcomes
Norah Terrault, MD, MPH
Vicente Soriano, MD, PhD

2016 Conference Program and Abstracts
Click below to download the complete 2016 Program and Abstracts book in PDF format.

Requires free Acrobat Reader Plugin Software